T
Tanja Badovinac-Crnjevic
Researcher at Harvard University
Publications - 9
Citations - 1323
Tanja Badovinac-Crnjevic is an academic researcher from Harvard University. The author has contributed to research in topics: Breast cancer & Aromatase inhibitor. The author has an hindex of 8, co-authored 9 publications receiving 1049 citations. Previous affiliations of Tanja Badovinac-Crnjevic include Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Planning cancer control in Latin America and the Caribbean
Paul E. Goss,Brittany L. Lee,Brittany L. Lee,Tanja Badovinac-Crnjevic,Kathrin Strasser-Weippl,Yanin Chavarri-Guerra,Jessica St. Louis,Cynthia Villarreal-Garza,Karla Unger-Saldaña,Mayra Ferreyra,Marcio Debiasi,Pedro E.R. Liedke,Diego Touya,Gustavo Werutsky,Michaela J. Higgins,Lei Fan,Claudia Vasconcelos,Eduardo Cazap,Carlos S. Vallejos,Alejandro Mohar,Felicia Marie Knaul,Héctor Arreola,Rekha Batura,Silvana Luciani,Richard Sullivan,Dianne M. Finkelstein,Sergio Daniel Simon,Carlos H. Barrios,Rebecca S. Kightlinger,Andres Gelrud,Vladimir Bychkovsky,Gilberto Lopes,Gilberto Lopes,Stephen Stefani,Marcelo Blaya,Fabiano Hahn Souza,Franklin Santana Santos,Alberto Kaemmerer,Evandro de Azambuja,Andres Felipe Cardona Zorilla,Raúl Murillo,Jose Jeronimo,Vivien Tsu,André Lopes Carvalho,Carlos Ferreira Gil,Cinthya Sternberg,Alfonso Dueñas-González,Dennis C. Sgroi,Mauricio Cuello,Rodrigo Fresco,Rui Manuel Reis,G. Masera,Raul Gabus,Raul C. Ribeiro,Raul C. Ribeiro,Renata Knust,Gustavo Ismael,Eduardo Rosenblatt,B. M. C. Roth,Luisa L. Villa,Argelia Lara Solares,Marta Ximena Leon,Isabel Torres-Vigil,Isabel Torres-Vigil,Alfredo Covarrubias-Gómez,Andrés Hernández,Mariela Bertolino,Gilberto Schwartsmann,Sergio Santillana,Francisco J. Esteva,Luis Fein,Max S. Mano,Henry L. Gomez,Marc Hurlbert,Alessandra Durstine,Gustavo S. Azenha +75 more
TL;DR: In this article, the authors present the findings of their Cancer Commission and their recommendations to encourage Latin American stakeholders to redouble their efforts to address this increasing cancer burden and to prevent it from worsening and threatening their societies.
Journal ArticleDOI
Challenges to effective cancer control in China, India, and Russia
Paul E. Goss,Kathrin Strasser-Weippl,Brittany L. Lee-Bychkovsky,Brittany L. Lee-Bychkovsky,Lei Fan,Lei Fan,Junjie Li,Junjie Li,Yanin Chavarri-Guerra,Pedro E.R. Liedke,C S Pramesh,Tanja Badovinac-Crnjevic,Yuri Sheikine,Yuri Sheikine,Zhu Chen,You-Lin Qiao,Z Shao,Yi-Long Wu,Daiming Fan,Louis W.C. Chow,Jun Wang,Qiong Zhang,Shiying Yu,Gordon C Shen,Gordon C Shen,Jie He,Arnie Purushotham,Richard Sullivan,Rajendra A. Badwe,Shripad Banavali,Reena Nair,Lalit Kumar,Purvish M. Parikh,Somasundarum Subramanian,Pankaj Chaturvedi,Subramania Iyer,Surendra S Shastri,Raghunadhrao Digumarti,Enrique Soto-Perez-de-Celis,Dauren Adilbay,Vladimir Semiglazov,Sergey Orlov,Dilyara Kaidarova,Ilya Tsimafeyeu,Sergei Tatishchev,Kirill D. Danishevskiy,Marc Hurlbert,Caroline Vail,Jessica St. Louis,A. Chan +49 more
TL;DR: The overall state of health and cancer control in each country is described and additional specific issues for consideration are described: for China, access to care, contamination of the environment, and cancer fatalism and traditional medicine; for India, affordability of care, provision of adequate health personnel, and sociocultural barriers to cancer control.
Journal ArticleDOI
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop,Sung Bae Kim,Antonio Gonzalez Martin,Patricia LoRusso,Jean-Marc Ferrero,Tanja Badovinac-Crnjevic,Silke Hoersch,Melanie Smitt,Hans Wildiers +8 more
TL;DR: Overall survival was significantly longer with trastuzumab emtansine versus treatment of physician's choice and the study was terminated according to the protocol.
Journal ArticleDOI
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study
Dennis C. Sgroi,Judy-Anne W. Chapman,Tanja Badovinac-Crnjevic,Elizabeth Zarella,Shemeica Binns,Yi Zhang,Catherine A. Schnabel,Mark G. Erlander,Kathleen I. Pritchard,Lei Han,Lois E. Shepherd,Paul E. Goss,Michael Pollak +12 more
TL;DR: A retrospective study is an independent validation of the prognostic performance of BCI in a prospective trial, finding that BCI had a strong prognostic effect on RFS in patients with early-stage breast cancer treated with tamoxifen alone or with tamxifen and octreotide.
Journal ArticleDOI
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial
Paul E. Goss,Dawn L. Hershman,Angela M. Cheung,James N. Ingle,Sundeep Khosla,Vered Stearns,Haji Chalchal,Kendrith M. Rowland,Hyman B. Muss,Hannah M. Linden,Judite Scher,Kathleen I. Pritchard,C. Elliott,Tanja Badovinac-Crnjevic,Jessica St. Louis,Judith Anne W. Chapman,Lois E. Shepherd +16 more
TL;DR: The results demonstrate that adjuvant treatment with aromatase inhibitors can be considered for breast cancer patients who have T-scores less than -2·0 and show that exemestane-a mildly androgenic steroid-might have a less detrimental effect on bone than non-steroidal anastrozole.